SnoN Residue (1-366) Attenuates Hypertrophic Scars Through Resistance to Transforming Growth Factor-β1-induced Degradation

Overview

Journal Lab Invest

Specialty Pathology

Date 2019 Aug 15

PMID 31409891

Citations 3

Authors

Gui-Fang Sun

Hong-Chang Li

Yue-Ping Zhan

Xiao-Fen Zhang

Li-Yun Pan

Ya-Feng Chen

Ke Xu

Dian-Xu Feng

Affiliations

Soon will be listed here.

Abstract

Hypertrophic scars (HSs) are characterized by fibroblast hyperproliferation and excessive matrix deposition. During wound healing, transforming growth factor (TGF)-β1/Smad signaling acts as a key regulator. As a transcriptional corepressor of TGF-β1/Smads, SnoN is expressed at low levels in many fibrotic diseases due to TGF-β1/Smad-induced degradation. SnoN residue (1-366; SR) is resistant to TGF-β1-induced degradation. However, the expression and role of SR in HSs are unknown. Here, we inhibited TGF-β1/Smad signaling via overexpression of SR to block fibroblast transdifferentiation, proliferation, and collagen deposition during HS formation. Our results showed that SnoN was downregulated in HS fibroblasts (HSFs) owing to TGF-β1/Smad-induced degradation. Overexpression of SR in normal human dermal fibroblasts (NHDFs) and HSFs successfully blocked phosphorylation of Smad2 and Smad3, thereby inhibiting NHDF transdifferentiation and HSF proliferation and reducing type I collagen (ColI) and type III collagen (ColIII) production and secretion. In addition, we applied overexpressed full-length SnoN (SF) and SR to wound granulation tissue in a rabbit model of HSs. SR reduced wound scarring, improved collagen deposition and arrangement of scar tissue, and decreased mRNA and protein expression of ColI, ColIII, and α-smooth muscle actin (α-SMA) more effectively than SF in vivo. These results suggest that SR could be a promising therapy for the prevention of HS.

Citing Articles

BMS-202, a PD-1/PD-L1 inhibitor, decelerates the pro-fibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways.

Cai Y, Xiao M, Li X, Zhou S, Sun Y, Yu W Immun Inflamm Dis. 2022; 10(10):e693.

PMID: 36169254 PMC: 9449589. DOI: 10.1002/iid3.693.

USP15 Enhances the Proliferation, Migration, and Collagen Deposition of Hypertrophic Scar-Derived Fibroblasts by Deubiquitinating TGF-βR1 In Vitro.

Tu L, Lin Z, Huang Q, Liu D Plast Reconstr Surg. 2021; 148(5):1040-1051.

PMID: 34546211 PMC: 8542080. DOI: 10.1097/PRS.0000000000008488.

The Ubiquitin Proteasome System and Skin Fibrosis.

Shen W, Zhang Z, Ma J, Lu D, Lyu L Mol Diagn Ther. 2021; 25(1):29-40.

PMID: 33433895 DOI: 10.1007/s40291-020-00509-z.

References

Gauglitz G, Korting H, Pavicic T, Ruzicka T, Jeschke M . Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2010; 17(1-2):113-25. PMC: 3022978. DOI: 10.2119/molmed.2009.00153. View

Zhu Z, Ding J, Shankowsky H, Tredget E . The molecular mechanism of hypertrophic scar. J Cell Commun Signal. 2013; 7(4):239-52. PMC: 3889252. DOI: 10.1007/s12079-013-0195-5. View

Li B, Wang J . Fibroblasts and myofibroblasts in wound healing: force generation and measurement. J Tissue Viability. 2009; 20(4):108-20. PMC: 2891362. DOI: 10.1016/j.jtv.2009.11.004. View

Leask A, Abraham D . TGF-beta signaling and the fibrotic response. FASEB J. 2004; 18(7):816-27. DOI: 10.1096/fj.03-1273rev. View

Yano H, Hamanaka R, Nakamura M, Sumiyoshi H, Matsuo N, Yoshioka H . Smad, but not MAPK, pathway mediates the expression of type I collagen in radiation induced fibrosis. Biochem Biophys Res Commun. 2012; 418(3):457-63. DOI: 10.1016/j.bbrc.2012.01.039. View

Tanriverdi-Akhisaroglu S, Menderes A, Oktay G . Matrix metalloproteinase-2 and -9 activities in human keloids, hypertrophic and atrophic scars: a pilot study. Cell Biochem Funct. 2009; 27(2):81-7. DOI: 10.1002/cbf.1537. View

Singer A, Huang S, Huang J, McClain S, Romanov A, Rooney J . A novel TGF-beta antagonist speeds reepithelialization and reduces scarring of partial thickness porcine burns. J Burn Care Res. 2009; 30(2):329-34. DOI: 10.1097/BCR.0b013e31819a6369. View

Lu L, Saulis A, Liu W, Roy N, Chao J, Ledbetter S . The temporal effects of anti-TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J Am Coll Surg. 2005; 201(3):391-7. DOI: 10.1016/j.jamcollsurg.2005.03.032. View

Penn J, Grobbelaar A, Rolfe K . The role of the TGF-β family in wound healing, burns and scarring: a review. Int J Burns Trauma. 2012; 2(1):18-28. PMC: 3415964. View

10.

Chu Y, Guo F, Li Y, Li X, Zhou T, Guo Y . A novel truncated TGF-beta receptor II downregulates collagen synthesis and TGF-beta I secretion of keloid fibroblasts. Connect Tissue Res. 2008; 49(2):92-8. DOI: 10.1080/03008200801913924. View

11.

Goumans M, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, Ten Dijke P . Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 2002; 21(7):1743-53. PMC: 125949. DOI: 10.1093/emboj/21.7.1743. View

12.

Goumans M, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C . Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell. 2003; 12(4):817-28. DOI: 10.1016/s1097-2765(03)00386-1. View

13.

Evans R, Tian Y, Steadman R, Phillips A . TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp Cell Res. 2003; 282(2):90-100. DOI: 10.1016/s0014-4827(02)00015-0. View

14.

Li P, Liu P, Xiong R, Chen X, Zhao Y, Lu W . Ski, a modulator of wound healing and scar formation in the rat skin and rabbit ear. J Pathol. 2011; 223(5):659-71. DOI: 10.1002/path.2831. View

15.

Lee J, Tutela J, Zoumalan R, Thanik V, Nguyen P, Varjabedian L . Inhibition of Smad3 expression in radiation-induced fibrosis using a novel method for topical transcutaneous gene therapy. Arch Otolaryngol Head Neck Surg. 2010; 136(7):714-9. DOI: 10.1001/archoto.2010.107. View

16.

Katzel E, Wolenski M, Loiselle A, Basile P, Flick L, Langstein H . Impact of Smad3 loss of function on scarring and adhesion formation during tendon healing. J Orthop Res. 2010; 29(5):684-93. PMC: 3191491. DOI: 10.1002/jor.21235. View

17.

Kopp J, Preis E, Said H, Hafemann B, Wickert L, Gressner A . Abrogation of transforming growth factor-beta signaling by SMAD7 inhibits collagen gel contraction of human dermal fibroblasts. J Biol Chem. 2005; 280(22):21570-6. DOI: 10.1074/jbc.M502071200. View

18.

Stroschein S, Wang W, Zhou S, Zhou Q, Luo K . Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science. 1999; 286(5440):771-4. DOI: 10.1126/science.286.5440.771. View

19.

Deheuninck J, Luo K . Ski and SnoN, potent negative regulators of TGF-beta signaling. Cell Res. 2008; 19(1):47-57. PMC: 3103856. DOI: 10.1038/cr.2008.324. View

20.

Bonni S, Wang H, Causing C, Kavsak P, Stroschein S, Luo K . TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat Cell Biol. 2001; 3(6):587-95. DOI: 10.1038/35078562. View